Navigation Links
Micromet to Present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on March 4, 2008
Date:2/29/2008

BETHESDA, Md., Feb. 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on Tuesday, March 4, 2008, at 10:30 am ET at the W Hotel in New York.

Dr. Itin's presentation will be available on Micromet's website at http://www.micromet-inc.com following the event.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the most advanced antibody in Micromet's product pipeline developed using the BiTE(R) antibody technology platform, is being developed in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (TRC093), a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Micromet to Present at Two Upcoming Investor Conferences
2. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
3. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
4. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
5. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... healthcare organizations to build connected digital health applications, announced a partnership with Redox, ... users to seamlessly connect to many clinical systems while keeping data secure in ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... its $200M operational capacity with its strategic internal leadership to provide clients ... quality and operational management. With office locations in North Carolina, Massachusetts, ...
(Date:2/21/2017)... --  Logicalis Healthcare Solutions , the healthcare-focused practice within ... provider ( www.us.logicalis.com ), today announced a new service ... service will help hospital CIOs make the best use ... and other clinicians immediate access to a pool of ... hospital IT staff to focus on broader issues such ...
Breaking Biology Technology:
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
Breaking Biology News(10 mins):